SCHEMBL24137502

SCHEMBL24137502

Nc1n[nH]c2cc(-c3cnc(NCc4ccc(Cl)cc4)nc3)ccc12

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ JAK2 O60674 1/20 0.48
▸ PDPK1 O15530 8/20 0.47
▸ SGK1 O00141 6/20 0.46
▸ MKNK1 Q9BUB5 2/20 0.44
▸ MKNK2 Q9HBH9 2/20 0.44
▸ VNN1 O95497 1/20 0.43
▸ AURKA O14965 2/20 0.42
▸ TGFBR1 P36897 2/20 0.42
▸ AURKB Q96GD4 2/20 0.42
▸ CHUK O15111 1/20 0.42
▸ RPS6KB1 P23443 1/20 0.42
▸ CDK2 P24941 1/20 0.42
▸ KDR P35968 1/20 0.42
▸ SYK P43405 1/20 0.42
▸ JAK3 P52333 1/20 0.42
▸ ROCK1 Q13464 1/20 0.42
▸ MAP3K5 Q99683 1/20 0.42
▸ HDAC3 O15379 1/20 0.42
▸ HDAC1 Q13547 1/20 0.42
▸ HDAC2 Q92769 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25933239 0.88 ABL1 (0.54) JAK2PDPK1SGK1AURKATGFBR1
SCHEMBL24137503 0.88 MAP2K4 (0.55) JAK2PDPK1SGK1MKNK1MKNK2
SCHEMBL24137787 0.88 JAK2 (0.61) JAK2PDPK1SGK1MKNK1MKNK2
SCHEMBL24137919 0.87 MKNK1 (0.57) JAK2PDPK1SGK1MKNK1MKNK2
SCHEMBL24137524 0.85 SGK1 (0.48) JAK2PDPK1SGK1MKNK1MKNK2
SCHEMBL24137497 0.85 MAP2K4 (0.54) JAK2PDPK1VNN1AURKATGFBR1
SCHEMBL25933252 0.83 JAK2 (0.52) JAK2PDPK1SGK1MKNK1MKNK2
SCHEMBL24137797 0.82 JAK2 (0.51) JAK2PDPK1SGK1MKNK1MKNK2
SCHEMBL24137793 0.82 MAPK1 (0.48) JAK2PDPK1VNN1
SCHEMBL24137526 0.82 BTK (0.45) JAK2PDPK1SGK1AURKATGFBR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230234935-A1 KINASE INHIBITOR COMPOUNDS AND COMPOSITIONS AND METHODS OF USE ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI 2023-07-27 — — US disclosed
US-20230234935-A1 KINASE INHIBITOR COMPOUNDS AND COMPOSITIONS AND METHODS OF USE ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI 2023-07-27 — — US disclosed
WO-2021263129-A1 KINASE INHIBITOR COMPOUNDS AND COMPOSITIONS AND METHODS OF USE ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) 2021-12-30 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230234935-A1 KINASE INHIBITOR COMPOUNDS AND COMPOSITIONS AND METHODS OF USE PACSIN2, MAP3K20, PHKG1 JAK2 228/4885PDPK1 123/4885SGK1 191/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback